GOSS vs. SABS

Last updated Apr 1, 2026

Compare and contrast key facts about Gossamer Bio, Inc. (GOSS) and SAB Biotherapeutics, Inc. (SABS).

Performance

GOSS vs. SABS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Gossamer Bio, Inc. (GOSS) and SAB Biotherapeutics, Inc. (SABS). The values are adjusted to include any dividend payments, if applicable.

GOSS vs. SABS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
GOSS Gossamer Bio, Inc.	-89.40%	242.69%	-0.87%	-57.95%	-80.81%	5.70%
SABS SAB Biotherapeutics, Inc.	2.41%	-1.43%	-44.81%	16.55%	-92.45%	-23.05%

Fundamentals

EPS GOSS : -$0.69 SABS : $0.27
Total Revenue (TTM) GOSS : $44.05M SABS : $0.00
Gross Profit (TTM) GOSS : $44.05M SABS : -$2.37M
EBITDA (TTM) GOSS : -$145.96M SABS : $16.91M

Returns By Period

In the year-to-date period, GOSS achieves a -89.40% return, which is significantly lower than SABS's 2.41% return.

GOSS

• 1D: 2.66%
• 1M: -22.69%
• YTD: -89.40%
• 6M: -87.51%
• 1Y: -70.14%
• 3Y*: -36.12%
• 5Y*: -48.81%
• 10Y*: —

SABS

• 1D: 1.32%
• 1M: -6.59%
• YTD: 2.41%
• 6M: 90.55%
• 1Y: 181.62%
• 3Y*: -4.52%
• 5Y*: -47.81%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

GOSS vs. SABS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GOSS

GOSS Risk / Return Rank: 19
GOSS Sharpe Ratio Rank: 17
GOSS Sortino Ratio Rank: 31
GOSS Omega Ratio Rank: 31
GOSS Calmar Ratio Rank: 13
GOSS Martin Ratio Rank: 1

SABS

SABS Risk / Return Rank: 90
SABS Sharpe Ratio Rank: 91
SABS Sortino Ratio Rank: 90
SABS Omega Ratio Rank: 87
SABS Calmar Ratio Rank: 93
SABS Martin Ratio Rank: 91

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GOSS vs. SABS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Gossamer Bio, Inc. (GOSS) and SAB Biotherapeutics, Inc. (SABS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GOSS	SABS	Difference
Sharpe ratio Return per unit of total volatility	-0.57	2.07	-2.64
Sortino ratio Return per unit of downside risk	0.04	2.81	-2.77
Omega ratio Gain probability vs. loss probability	1.01	1.35	-0.35
Calmar ratio Return relative to maximum drawdown	-0.79	4.70	-5.48
Martin ratio Return relative to average drawdown	-2.06	11.89	-13.95
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GOSS vs. SABS - Sharpe Ratio Comparison

The current GOSS Sharpe Ratio is -0.57, which is lower than the SABS Sharpe Ratio of 2.07. The chart below compares the historical Sharpe Ratios of GOSS and SABS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	GOSS	SABS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.57	2.07	-2.64
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.49	-0.43	-0.06
Sharpe Ratio (All Time) Calculated using the full available price history	-0.47	-0.43	-0.03

Correlation

The correlation between GOSS and SABS is 0.11, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

GOSS vs. SABS - Dividend Comparison

Neither GOSS nor SABS has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

GOSS vs. SABS - Drawdown Comparison

The maximum GOSS drawdown since its inception was -98.81%, roughly equal to the maximum SABS drawdown of -99.01%. Use the drawdown chart below to compare losses from any high point for GOSS and SABS.

Drawdown Indicators

	GOSS	SABS	Difference
Max Drawdown Largest peak-to-trough decline	-98.81%	-99.01%	+0.20%
Max Drawdown (1Y) Largest decline over 1 year	-91.56%	-33.80%	-57.76%
Max Drawdown (5Y) Largest decline over 5 years	-97.85%	-99.01%	+1.16%
Current Drawdown Current decline from peak	-98.77%	-96.59%	-2.18%
Average Drawdown Average peak-to-trough decline	-70.70%	-77.39%	+6.69%
Ulcer Index Depth and duration of drawdowns from previous peaks	34.87%	13.36%	+21.51%

Volatility

GOSS vs. SABS - Volatility Comparison

Gossamer Bio, Inc. (GOSS) has a higher volatility of 39.73% compared to SAB Biotherapeutics, Inc. (SABS) at 22.06%. This indicates that GOSS's price experiences larger fluctuations and is considered to be riskier than SABS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GOSS	SABS	Difference
Volatility (1M) Calculated over the trailing 1-month period	39.73%	22.06%	+17.67%
Volatility (6M) Calculated over the trailing 6-month period	173.90%	50.47%	+123.43%
Volatility (1Y) Calculated over the trailing 1-year period	124.02%	88.72%	+35.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	100.18%	111.32%	-11.14%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	92.33%	109.82%	-17.49%

Financials